Introduction and Scale-Up of New and Lesser-Used Postpartum Hemorrhage Medicines (NLUM-PPH) Catalytic Opportunity Fund (COF)

Milka Dinev | Reproductive Health Supplies Coalition
About the COF

This is a pool of funds, managed by the RHSC and CHAI and funded by MSD for Mothers* and FCDO, is intended to increase access to new and lesser-used medicines for postpartum hemorrhage (NLUM-PPH) capable of preventing and treating PPH. This includes heat-stable carbetocin (HSC) for prevention of PPH and tranexamic acid (TXA) for the treatment of PPH. The goal is to provide funding for government-endorsed, catalytic preparatory activities that drive quality, new and lesser-used PPH medicines introduction and/or scale-up in low- and lower-middle-income countries.

* MSD for Mothers is an initiative of Merck & Co., Inc., Rahway, NJ, USA.
Catalytic Opportunities
Activities that enable increased efficiency and/or effectiveness of medicine introduction OR activities that are critical to achieve a successful medicine introduction.
Should demonstrate how they will lead to tangible, time-bound results for scale-up—specifically, leading to a sustainable increase in availability of quality NLU PPH medicines.

Sustainability and Country Ownership
COF activities must be government-endorsed (e.g., relevant department involved in medicine introduction and/or maternal and neonatal child health).
Government should explicitly state there is adequate NLU PPH medicine stock or a procurement plan in place to ensure adequate stock to support activities.
COF activities should demonstrate how they utilize or build sustainable processes, systems, and/or resources for scale-up.
Eligibility Requirements

Country Eligibility

• Low- or lower-middle-income countries.
• Included NLU PPH medicines into MOH Essential Medicines List and/or clinical guidelines.
• NLU PPH medicines have local regulatory approval or written commitment to pursue an importation waiver by the project start.
• Countries that have already made the decision to introduce the NLU PPH medicines.
Eligibility Requirements

Medicine Eligibility

• Heat-stable carbetocin (HSC) for the prevention of PPH and tranexamic acid (TXA) for the treatment of PPH.

• Activities to scale HSC alone or with TXA are eligible. Activities to scale TXA alone are not eligible.
Eligibility Requirements

Fund Parameters

- Implementing timeframes up to nine months.
- Funding ceiling of USD$100,000 per application. However, there is no limit to the number of distinct applications that can be submitted per applicant.
- Applications are accepted on a rolling basis.